Home
Vendors

Kymera

Kymera
Kymera
22 Solutions
Do you work for Kymera ?
Contact us to update this profile
All information is currently provided by Contentree

0 Solution Set

Solutions


IRAK4 Degradation Abrogates Cytokine Release and Improves Disease Endpoints
Case Study IRAK4 Degradation Abrogates Cytokine Release and Improves…
Kymera

Multiple Mediators of Inflammation Correlate with IRAK4 Case Study
Case Study Multiple Mediators of Inflammation Correlate with IRAK4 Case…
Kymera

Discovery of potent and selective STAT3 targeted protein degraders with excellent in vitro and in vivo ADME properties Case Study
Case Study Discovery of potent and selective STAT3 targeted protein…
Kymera

Targeting STAT3 withSelective Protein Degraders for the Treatment of PTCL Case Study
Case Study Targeting STAT3 withSelective Protein Degraders for the…
Kymera

KT-413, a Novel IRAKIMiDDegrader of IRAK4 and IMiDSubstrates Case Study
Case Study KT-413, a Novel IRAKIMiDDegrader of IRAK4 and IMiDSubstrates…
Kymera

Mechanisms Underlying Synergistic Activity of KT-413, a Targeted Degrader of IRAK4 and IMiD Substrates in Hematopoietic Cancers
Case Study Mechanisms Underlying Synergistic Activity of KT-413, a Targeted…
Kymera

Targeted protein degradation in oncology and beyond Case study
Case Study Targeted protein degradation in oncology and beyond Case study
Kymera

Drugging Tissue - Restricted E3 Ligases
Case Study Drugging Tissue - Restricted E3 Ligases
Kymera

Targeting MYD88-Mutant DLBCL with IRAKIMiDs: A Comparison to IRAK4 Kinase Inhibition and Evaluation of Synergy with Rational Combinations Case Study
Case Study Targeting MYD88-Mutant DLBCL with IRAKIMiDs: A Comparison to…
Kymera

To Evaluate Cutaneous & Circulating Biomarkers for a Novel IRAK4-Targeted Therapeutic Case Study
Case Study To Evaluate Cutaneous & Circulating Biomarkers for a Novel…
Kymera

Targeted Protein Degradation Beyond Oncology Case Study
Case Study Targeted Protein Degradation Beyond Oncology Case Study
Kymera

Mechanisms of Anti-Tumor Activity of STAT3 Degraders in Lymphoma Case Study
Case Study Mechanisms of Anti-Tumor Activity of STAT3 Degraders in Lymphoma…
Kymera

PK/PD RELATIONSHIP IN TARGETED PROTEIN DEGRADATION (TPD)
Case Study PK/PD RELATIONSHIP IN TARGETED PROTEIN DEGRADATION (TPD)
Kymera

KTX-120, A Novel IRAKIMiDDegrader of IRAK4 and IMiD Substrates, Shows Preferential Activity and Induces Regressions
Case Study KTX-120, A Novel IRAKIMiDDegrader of IRAK4 and IMiD Substrates,…
Kymera

Identification of highly potent and selective Interleukin-1 receptor
Case Study Identification of highly potent and selective Interleukin-1…
Kymera

A STAT3-Selective Targeted Protein Degrader Decreases The Immune-Suppressive Tumor Microenvironment
Case Study A STAT3-Selective Targeted Protein Degrader Decreases The…
Kymera

Small Molecule-Induced, Selective STAT3 Degradation Leads to Anti-Tumor Activity in STAT3-Dependent Heme Malignancies
Case Study Small Molecule-Induced, Selective STAT3 Degradation Leads to…
Kymera

A First-in-Class Selective and Potent IRAK4 Degrader Case Study
Case Study A First-in-Class Selective and Potent IRAK4 Degrader Case Study
Kymera

KYM001, first in class oral IRAK4 protein degraders Case Study
Case Study KYM001, first in class oral IRAK4 protein degraders Case Study
Kymera

IRAK4 Degraders for MYD88 Mutant Lymphoma
Case Study IRAK4 Degraders for MYD88 Mutant Lymphoma
Kymera

2953 Targeted Degradation of IRAK4 Protein Via Heterobifunctional Small Molecules for Treatment of MYD88 Mutant Lymphoma Case Study
Case Study 2953 Targeted Degradation of IRAK4 Protein Via…
Kymera

Discovery of KYM-003, a potent and selective STAT3 degrader with anti-tumor Case Study
Case Study Discovery of KYM-003, a potent and selective STAT3 degrader with…
Kymera
© 2025 Contentree.  All Rights Reserved   |   Privacy and Cookies   |   Legal   |   Do not sell my info